| gemcitabine / Generic mfg. |
NCT00305734: Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer |
|
|
| Completed | 2 | 50 | US | bortezomib, LDP 341, MLN341, VELCADE, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, laboratory biomarker analysis | National Cancer Institute (NCI) | Recurrent Nasopharyngeal Cancer, Stage IV Nasopharyngeal Cancer | 07/07 | | | |
NCT00436800: Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma |
|
|
| Completed | 2 | 41 | RoW | Gemcitabine, Oxaliplatin | Sanofi | Nasopharyngeal Neoplasms | 10/08 | 10/08 | | |
NCT00603915: A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer |
|
|
| Completed | 2 | 20 | Canada | Gemcitabine, Carboplatin/Cisplatin, erlotinib | University Health Network, Toronto, Hoffmann-La Roche | Nasopharyngeal Cancer | 12/10 | 04/11 | | |
NCT00697905: Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma |
|
|
| Completed | 2 | 18 | RoW | Gemcitabine, Carboplatin, Cisplatin, 5-fluorouracil (5-FU) | Ministry of Health, Malaysia | Nasopharyngeal Carcinoma | 05/11 | 05/11 | | |
NCT01596868: GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China |
|
|
| Completed | 2 | 60 | RoW | gemcitabine and cisplatin, GP, docetaxel and cisplatin, TP | Air Force Military Medical University, China | Nasopharyngeal Squamous Cell Carcinoma, Toxicity Due to Radiotherapy | 10/13 | 10/13 | | |
